{"url_path":"/sec/kapa/8-k/2026-06-30/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-031328-index.html","accession_number":"0001493152-26-031328","cik":"0001962011","ticker":"KAPA","issuer_name":"Kairos Pharma, LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-031328-index.html","primary_entity_key":"0001962011","primary_entity_name":"Kairos Pharma, LTD."},"word_count":501,"has_tables":true,"body_markdown":"**Item\n5.07**\n**Submission\nof Matters to a Vote of Security Holders.**\n\n \n\nOn\nJune 29, 2026, Kairos Pharma Ltd. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”)\nat which the Company’s stockholders considered and voted on five proposals, each of which is described in more detail in the Company’s\ndefinitive proxy statement filed with the Securities and Exchange Commission on May 22, 2026, as supplemented on May 26, 2026. At the\nAnnual Meeting, there were a total of 21,411,198 shares of common stock eligible to vote, with each share representing one vote, of which\n13,450,506 shares of common stock were voted in person or by proxy, representing 62.81% of the votes eligible to be cast.\nThe final voting results for each matter are set forth in more detail below.\n\n \n\n**1.**\n**Election\nof Directors.**\n\n \n\nAll\nof the following four nominees were elected to the Company’s board of directors, in accordance with the voting results listed below,\nto serve for a term of one year, until the next annual meeting and until their successors have been duly elected and have qualified.\n\n \n\nNominee\n \nFor\n \n \nAgainst\n \n \nWithheld\n \n \nBroker\nNon-Votes\n \n\nJohn\nS. Yu, M.D.\n \n \n8,189,240\n \n \n \n0\n \n \n \n381,505\n \n \n \n4,879,761\n \n\nHyun\nW. Bae, M.D.\n \n \n8,438,397\n \n \n \n0\n \n \n \n132,348\n \n \n \n4,879,761\n \n\nHansoo\nMichael Keyoung, M.D., Ph.D.\n \n \n8,438,397\n \n \n \n0\n \n \n \n132,348\n \n \n \n4,879,761\n \n\nRahul\nSighvi, Sci.D., MBA\n \n \n8,414,867\n \n \n \n0\n \n \n \n155,878\n \n \n \n4,879,761\n \n\n \n\n**2.**\n**Ratification\nof the Company’s Independent Auditors.**\n\n \n\nStockholders\nratified the appointment of Weinberg & Company, P.A. as the Company’s independent registered public accounting firm for the\nfiscal year ending December 31, 2026, in accordance with the voting results below.\n\n \n\nFor \nAgainst \nAbstain\n\n13,241,007 \n169,047 \n40,452\n\n \n\n**3.**\n**Approval of Amendment to Certificate of Incorporation.**\n\n \n\nStockholders\napproved, in accordance with the voting results below, an amendment to the Company’s certificate of incorporation to effect a reverse\nstock split of our common stock at a stock split ratio between 1:3 and 1:250, with the ultimate ratio to be determined by the Board of\nDirectors and implemented on one or more occasions at the discretion of the Board of Directors.\n\n \n\nFor\n \nAgainst\n \nAbstain\n\n11,232,321\n \n1,945,235\n \n272,950\n\n \n\n**4.**\n**Approval of the Company’s\nExecutive Compensation.**\n\n \n\nStockholders\napproved (on an advisory basis) the Company’s executive compensation.\n\n \n\nFor\n \nAgainst\n \nAbstain\n \nBroker\nNon-Votes\n\n7,784,120\n \n782,829\n \n3,796\n \n4,879,761\n\n \n\n**5.**\n**Approval\nof Amendments to Equity Incentive Plan.**\n\n \n\nStockholders\napproved (i) an increase of an additional 5,000,000 shares of common stock available for awards under the 2023 Equity Incentive Plan\nand (ii) an evergreen provision providing for an automatic 5% annual increase in the shares of common stock available for issuance under\nthe 2023 Equity Incentive Plan over a period of ten years.\n\n \n\nFor\n \nAgainst\n \nAbstain\n \nBroker\nNon-Votes\n\n7,067,866\n \n1,480,645\n \n22,234\n \n4,879,761\n\n \n\n2\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\nDated:\nJune 30, 2026\n \n\n \n \n \n\nKAIROS\nPHARMA LTD.\n \n\n \n \n \n\nBy:\n*/s/\nJohn S. Yu*\n \n\nName:\n\n John\nS. Yu\n \n\nTitle:\nChief\nExecutive Officer and Chairman of the Board of Directors\n \n\n \n\n3"}